Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 5/20 | 0.63 |
| ▸ | ITGA2B | P08514 | 5/20 | 0.63 |
| ▸ | MMP2 | P08253 | 9/20 | 0.55 |
| ▸ | MMP9 | P14780 | 7/20 | 0.55 |
| ▸ | ADAMTS4 | O75173 | 1/20 | 0.55 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.51 |
| ▸ | ADAMTS5 | Q9UNA0 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | MMP1 | P03956 | 1/20 | 0.49 |
| ▸ | MMP3 | P08254 | 1/20 | 0.49 |
| ▸ | MMP7 | P09237 | 1/20 | 0.49 |
| ▸ | MMP13 | P45452 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3311910 | 1.00 | ITGB3 (0.63) | ITGB3ITGA2BMMP2MMP9ADAMTS4 | |
| SCHEMBL11979693 | 0.91 | MMP2 (0.60) | ITGB3ITGA2BMMP2MMP9ADAMTS4 | |
| SCHEMBL6032775 | 0.86 | ITGB3 (0.64) | ITGB3ITGA2BMMP2MMP9ADAMTS4 | |
| SCHEMBL3306554 | 0.84 | ITGB3 (0.54) | ITGB3ITGA2BALDH1A1POLB | |
| SCHEMBL5966471 | 0.84 | MMP2 (0.58) | ITGB3ITGA2BMMP2MMP9ADAMTS4 | |
| SCHEMBL5966474 | 0.84 | MMP2 (0.58) | ITGB3ITGA2BMMP2MMP9ADAMTS4 | |
| SCHEMBL7622370 | 0.83 | ITGB3 (0.61) | ITGB3ITGA2BMMP2MMP9ADAMTS4 | |
| SCHEMBL5603960 | 0.83 | ITGB3 (0.61) | ITGB3ITGA2BMMP2MMP9ADAMTS4 | |
| SCHEMBL16358922 | 0.83 | MMP2 (0.52) | ITGB3ITGA2BMMP2MMP9ADAMTS4 | |
| SCHEMBL4067325 | 0.83 | ITGB3 (0.61) | ITGB3ITGA2BMMP2MMP9ADAMTS4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140107027-A1 | METHODS AND COMPOSITIONS FOR TREATING AMYLOID-RELATED DISEASES | BHI LIMITED PARTNERSHIP (CA) | 2014-04-17 | — | — | US | disclosed |
| US-8642801-B2 | Methods and compositions for treating amyloid-related diseases | BHI LIMITED PARTNERSHIP (CA) | 2014-02-04 | — | — | US | disclosed |
| US-20100113591-A1 | METHODS AND COMPOSITIONS FOR TREATING AMYLOID-RELATED DISEASES | BELLUS HEALTH (INTERNATIONAL) LIMITED (CH) | 2010-05-06 | — | — | US | disclosed |
| US-7414076-B2 | Methods and compositions for treating amyloid-related diseases | NEUROCHEM (INTERNATIONAL) LIMITED (CH) | 2008-08-19 | — | — | US | disclosed |
| US-20070010573-A1 | Methods and compositions for treating amyloid-related diseases | BELLUS HEALTH (INTERNATIONAL) LIMITED (CH) | 2007-01-11 | — | — | US | disclosed |
| US-20050096385-A1 | Methods and compositions for treating amyloid-related diseases | BHI LIMITED PARTNERSHIP (CA) | 2005-05-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140107027-A1 | METHODS AND COMPOSITIONS FOR TREATING AMYLOID-RELATED DISEASES | APP, PSEN1, PSEN2 | ITGB3 3213/4885ITGA2B 3161/4885MMP2 1001/4885 |
| US-20100113591-A1 | METHODS AND COMPOSITIONS FOR TREATING AMYLOID-RELATED DISEASES | APP, PSEN1, PSEN2 | ITGB3 3213/4885ITGA2B 3161/4885MMP2 1001/4885 |
| US-20050096385-A1 | Methods and compositions for treating amyloid-related diseases | APP, PSEN1, PSEN2 | ITGB3 3213/4885ITGA2B 3161/4885MMP2 1001/4885 |
| US-20070010573-A1 | Methods and compositions for treating amyloid-related diseases | APP, PSEN1, PSEN2 | ITGB3 3213/4885ITGA2B 3161/4885MMP2 1001/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.